CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development

Sep 8, 2021

The investment provides CaaMTech with capital to advance compounds from its library into clinical trials


CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development

CaaMTech logo on green background

ISSAQUAH, Wash. - September 8, 2021 - (Newswire.com)

CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing round, led by Noetic Fund. The oversubscribed round of funding will be deployed to support CaaMTech's industry-leading cross-disciplinary science program, expand the company's leadership team, and advance its foremost drug development candidates into human trials.

"This Series A investment further substantiates our hypothesis that the future of the psychedelics industry depends on the strength of its foundation," said CaaMTech founder and CEO, Dr. Andrew Chadeayne. "Now that we have built that foundation, we are grateful to partner with Noetic for the next steps. Their industry leadership and experienced team make Noetic the optimal partner to help shepherd these drugs to the patients who need them most."

CaaMTech was founded in 2017 to fill the unmet need for pure, well-characterized psychedelic drugs. Since then, the company has produced an extensive library of novel, analytically pure compounds that are nearing advancement into human trials.

"CaaMTech's extensive patent library, scientific and research-laden focus, coupled with their impressive leadership team and an unwavering commitment to pursuing drug development within the psychedelic industry make them one of the most formidable companies in this space," said Sa'ad Shah, co-founder and managing partner of the Noetic Fund. "We could not be more excited about our support and investment in CaaMTech."

CaaMTech has led the psychedelics industry in fundamental research, publishing tens of peer-reviewed scientific research publications. Through collaborations with the NIH's Designer Drug Research Unit at the National Institute on Drug Abuse, the University of Massachusetts Dartmouth, and The Leibniz Institute for Natural Product Research, CaaMTech has built a cross-disciplinary team of world-class scientists, providing diverse subject matter expertise and a shared goal to advance the state of the art of the psychedelic industry. The successful completion of Series A funding will allow CaaMTech to continue its dedication to fundamental scientific research through continued academic collaboration while advancing individual drug candidates toward the clinic.

About CaaMTech
CaaMTech is the foremost drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech is improving the health and happiness of humankind by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation.

About Noetic
Noetic is a group of venture funds launched by Grey House Partners GP Inc. to invest in emerging and early-stage psychedelic and CNS companies, addressing global unmet healthcare needs such as mental health conditions, substance use disorders, and distinct inflammatory-related ailments. Noetic has built a team with the deep domain expertise required to appraise opportunities in this nascent sector: from neuroscience and pharmacology through to regulatory pathways and health economics. The firm is committed to scaling the disruptive potential of psychedelics in a responsible manner, with a core mission of supporting the development of innovative technologies that help define a healthy future for people and the planet.

Media Contact
Davis Wuolle
[email protected]
+1.510.747.9001




Press Release Service by Newswire.com

Original Source: CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development

More News

The uncomfortable truth about aquariums

Sep 22, 2026

The uncomfortable truth about aquariums

Young visitors watch the beluga whales at L'Oceanogràfic in Valencia, Spain. | Miguel Candela/SOPA Images/LightRocket via Getty Images This story appeared in Today, Explained, a daily newsletter that helps you understand the most compelling news and stories of the day. Subscribe here. Four beluga whales have died in a month at one of America’s top-rated aquariums — a tragic development and, arguably, a reason to revisit the ethics of zoos. (More on that in just a minute.) The latest cetacean casualty, a 26-year-old female named Osiris, died at Chicago’s Shedd Aquarium yesterday. She follows 34-year-old Beethoven, a longtime resident of the aquarium, as well as 20-year-old Rain and 23-year-old Peekachu, who died in late August and early September.    Osiris, Rain and Peekachu were all part of the Marineland diaspora: a group of four dolphins and 30 beluga whales that rescuers have worked to relocate since the 2024 closure of a scandal-plagued theme park in Niagara Falls, Canada. This summer, the animals were successfully transferred to aquariums and marine parks in the US and Spain. That was a frankly incredible undertaking involving padded shipping containers, a police-escorted convoy and a chartered plane.  But in some regards, the international flight wasn’t even the hardest part of the whales’ journeys. Some of the animals have struggled to thrive in their new environments — even when those environments are state-of-the-art, like Shedd.  In a blog post announcing Osiris’s death, the aquarium noted that its rescued whales had been under 24-hour supervision and receiving intensive, specialized care. The aquarium is still investigating the cause of death for all four whales.  Go a little deeper View Link Believe me when I tell you that it gives me no pleasure to write the following paragraphs. I really love aquariums. In fact, as a kid, I grew up visiting the now-shuttered and much-maligned Marineland.  But incidents like these back-to-back deaths should prompt us all to ask ourselves who aquariums and zoos are actually for. And the answer, I regret to tell you, is frequently not “the animals” — though zoos and aquariums have, since the mid-20th century, marketed themselves as both tourist attractions and important players in wildlife education and conservation.   As my colleague Kenny Torrella writes, these institutions and their defenders argue they protect animals in three ways: first, by raising money for wildlife conservation projects; second, by helping to reintroduce vulnerable species back into the wild; and third, by inspiring visitors to take an interest in the environment. The Shedd Aquarium’s motto, for instance, is “For Love of Waterkind.”  It’s worth scrutinizing those purported virtues, however — even when prestigious and reputable institutions like Shedd are making them. On one hand, there is merit to the claim that zoos and aquariums fundraise for wildlife conservation: In 2022, the latest year for which data is available, one group of accredited zoos and aquariums spent more than a quarter of a billion dollars on habitat projects.  The evidence is thinner on the other points, though. It’s incredibly rare for aquariums and zoos to reintroduce endangered species back into the wild — that’s very difficult to do. And surveys of zoo and aquarium visitors show that merely seeing a wild animal in a tourist setting doesn’t generally galvanize people on matters of welfare or stewardship. Living in captivity in that tourist setting, however, can be stressful (or worse) for the animals themselves.  But what would a humane alternative look like? Even if zoos and aquariums stopped catching animals in the wild, that would still leave many thousands who are injured, orphaned, born in captivity, or otherwise accustomed to human care.  When it comes to whales, one nonprofit advocacy organization is already working on an alternative: a 110-acre coastal sanctuary for “retired” whales. That project, however, is still a long way from completion. And in the meantime, it’s up to consumers to decide whether the stated benefits of zoos and aquariums outweigh the potential harms to the animals they exhibit. One link for later ➨ Beware the trap of “moral perfection.” We should all endeavor to live lives that embody our values, sure. But if you never board a plane because you care about the climate, or you never take your kid to zoos because you read the arguments above, then you might end up with a smaller, less-lived life. And that’s no good, either.  Before you go… Did you know…that there have been “revolutionary” advancements in Alzheimer’s treatments in just the past five years? Two new drugs both markedly slow the progress of dementia. Today’s trivia: Geography time! What country is bordered by Chad to the east and Mali to the west? Hint: It is the second-largest landlocked African nation. (You can find this and other brain puzzles in Vox’s daily crossword. Look for the answer in tomorrow’s edition.) Yesterday’s trivia: Yesterday we asked you for the classic Broadway star who first sang hits including “There’s No Business Like Show Business.” That would be Ethel Merman, whom one biographer dubbed “the most successful musical comedy performer of her generation.”

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Central News Today

Central News Today breaks down complex issues with unique perspective, bringing high-quality journalism to millions of readers around the world.

NEWSLETTER